Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review and economic evaluation
Tumor-Profiling-Tests zur Steuerung der adjuvanten Chemotherapieentscheidung bei lymphknotenpositivem frühem Brustkrebs: systematische Übersicht und ökonomische Bewertung
Health Technology Assessment · 2025-10 · 1-158
DOI: 10.3310/kgfd4040 ↗Auf einen Blick
Vier Tumor-Profiling-Tests wurden auf Nutzen und Kosteneffektivität zur Steuerung adjuvanter Chemotherapie bei frühem, hormonrezeptorpositivem, HER2-negativem Brustkrebs mit 1 bis 3 positiven Lymphknoten bewertet. Alle Tests lieferten Prognoseinformationen; zur prädiktiven Wirkung sind die Daten schwach.
Fragestellung
Wie wirksam und kosteneffektiv sind Oncotype DX, Prosigna, EPclin und MammaPrint im Vergleich zu keiner Testung für die Entscheidung über adjuvante Chemotherapie?
Methode
Systematische Übersicht; Literaturrecherche im April 2023 und aus einer früheren Übersicht. Ökonomische Analyse mit Review bestehender Modelle und eigenem Modell.
Ergebnisse
55 Artikel eingeschlossen, 42 zur prognostischen und prädiktiven Fähigkeit, 13 zum Einfluss auf Chemotherapieentscheidungen. Für Oncotype DX zeigten sich in RxPONDER und SWOG-8814 Hinweise auf heterogene Chemotherapievorteile; für Prosigna, EPclin und MammaPrint kein klarer Nachweis.
Einschränkungen
Begrenzte Daten zur Vorhersage des Chemotherapievorteils; Entscheidungswirkungsstudien bei lymphknotenpositiver Population nur für Oncotype DX; ökonomisches Modell beruht auf Annahmen.
Schlussfolgerung der Autor:innen
Alle vier Tests liefern prognostische Informationen zum Rückfallrisiko. Die Evidenz zur Vorhersage des relativen Chemotherapievorteils ist schwächer und überwiegend auf Oncotype DX beschränkt.
Kernaussagen
- Alle vier Tests zeigten prognostische Aussagekraft zum Rückfallrisiko.
- Für Oncotype DX gab es Hinweise auf einen prädiktiven Nutzen.
- Ökonomisch könnten Oncotype DX und EPclin bei postmenopausalen Subgruppen günstig sein.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Health Technology Assessment, 2025-10. Verfasst von Paul Tappenden und 9 weiteren Autor:innen. Beteiligte Einrichtung: Sheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, University of Sheffield, Sheffield, UK. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment programme.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Breast cancer is the most commonly diagnosed cancer in women in England. Breast cancer and chemotherapy treatment can impact upon patients’ quality of life and survival. Tumour profiling tests can help to identify whether patients will benefit from chemotherapy.
Objectives
To evaluate the effectiveness and cost-effectiveness of four tumour profiling tests (Oncotype DX, Prosigna, EPclin and MammaPrint), compared with current decision-making (no testing), to guide use of adjuvant chemotherapy in people with hormone-receptor positive, human epidermal growth factor receptor 2 negative, early-stage breast cancer with one to three positive lymph nodes. Methods and data sources A systematic review identified studies via a literature search in April 2023 and from our previous review. The economic analysis included a review of existing models and development of an independent model.
Results
Fifty-five articles were included, 42 for prognostic and predictive ability and 13 for impact on chemotherapy decisions. All four tests showed prognostic ability for determining risk of relapse. The RxPONDER randomised controlled trial of Oncotype DX indicated no chemotherapy benefit in post-menopausal lymph node-positive patients with a recurrence score of 0–25, but a statistically significant benefit in pre-menopausal patients with a recurrence score of 0–25. An older randomised controlled trial reanalysis (Southwest Oncology Group-8814) indicated lower relative chemotherapy benefit with lower recurrence score, with statistically significant interactions between recurrence score and chemotherapy benefit in some but not all analyses. There was no clear evidence of prediction of relative chemotherapy benefit for Prosigna, EPclin or MammaPrint. Decision impact studies in lymph node-positive populations in the United Kingdom and Europe were only available for Oncotype DX, and they reported a reduction of 12–75% in chemotherapy recommendations following testing. Based on the list prices of the tests and downstream treatments, the independent model suggests the following: Oncotype DX This test dominates current decision-making in post-menopausal lymph node-positive women, provided an assumption of predictive benefit holds, but the test is dominated if this assumption does not hold. The test is dominated by current decision-making in pre-menopausal lymph node-positive women. Prosigna The probabilistic incremental cost-effectiveness ratio for Prosigna versus current decision-making in post-menopausal lymph node-positive women is £39,357 per quality-adjusted life-year gained. EPclin The probabilistic incremental cost-effectiveness ratio for EPclin versus current decision-making in post-menopausal lymph node-positive women is £4113 per quality-adjusted life-year gained. MammaPrint Within clinical high-risk pre-/post-menopausal lymph node-positive women, MammaPrint is dominated by current decision-making.
Limitations
There are limited data on the prediction of chemotherapy benefit; evidence for Oncotype DX may support a predictive benefit, but this is uncertain. Decision impact studies in a lymph node-positive population were available only for Oncotype DX. The economic model relies on an assumption of predictive benefit for Oncotype DX, and broader assumptions around the way that Prosigna, MammaPrint and EPclin test results would affect chemotherapy decisions.
Conclusions
All four tests provide prognostic information on the risk of relapse. The evidence on prediction of relative chemotherapy benefit is weaker and mostly limited to Oncotype DX. The economic analyses indicate that Oncotype DX and EPclin may have favourable cost-effectiveness profiles in post-menopausal lymph node-positive subgroups, although this is uncertain. Study registration This study is registered as PROSPERO CRD42023425638. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis Programme (NIHR award ref: NIHR135822) and is published in full in Health Technology Assessment ; Vol. 29, No. 49. See the NIHR Funding and Awards website for further award information.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
- Department of Medicine, Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK.
- Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
ORCID-Profile: Paul Tappenden, Katy Cooper, Jean Hamilton, Gamze Nalbant, Munira Essat, Annabel Rayner, Ruth Wong, Nicolò Matteo Luca Battisti, Lynda Wyld, Uzma Asghar
Förderung
- Health Technology Assessment programme
Zitieren
APA
Tappenden, P., Cooper, K., Hamilton, J., Nalbant, G., Essat, M., Rayner, A., Wong, R., Battisti, N. M. L., Wyld, L., & Asghar, U. (2025). Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review and economic evaluation. Health Technology Assessment, 1-158. https://doi.org/10.3310/kgfd4040
Vancouver
Tappenden P, Cooper K, Hamilton J, Nalbant G, Essat M, Rayner A, et al. Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review and economic evaluation. Health Technology Assessment. 2025:1-158. doi:10.3310/kgfd4040
BibTeX
@article{Tappenden2025,
author = {Tappenden, Paul and Cooper, Katy and Hamilton, Jean and Nalbant, Gamze and Essat, Munira and Rayner, Annabel and Wong, Ruth and Battisti, Nicolò Matteo Luca and Wyld, Lynda and Asghar, Uzma},
title = {Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review and economic evaluation},
journal = {Health Technology Assessment},
year = {2025},
pages = {1--158},
doi = {10.3310/kgfd4040}
}
EUVIMED